Side-by-side · Research reference

MGFvsTestagen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED14/55 cited

BAnimal-MechanisticHUMAN-REVIEWED11/41 cited

MGF

IGF-1Ec Splice Variant · Muscle-Specific

IGF-1EcSplice variantArmakolas 2016

24-AASynthetic E-domain

Animal onlyHuman evidence

SQ · Research context only

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

01Mechanism of Action

Parameter

MGF

Testagen

Primary target

Satellite cells (Pax7+) in skeletal muscleMoore 2018

Testicular tissue; proposed nuclear DNA interaction

Pathway

Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

Downstream effect

Satellite cell proliferation, myoblast differentiation, muscle fiber repair

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Feedback intact?

—

Unknown — no HPG axis data

Origin

Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016 Vassilakos 2017

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Antibody development

—

02Dosage Protocols

Parameter

MGF

Testagen

Synthetic peptide

24-amino-acid E-domain sequence

Corresponds to human IGF-1Ec exons 4-6 region.

—

Rodent cardiac model

200 μg/kg via peptide-eluting microstructures

Post-MI injection; improved ejection fraction by 8 weeks.

—

Acute delivery (mouse MI)

Single bolus within 12 hrs post-infarctionShioura 2014

Delayed decompensation; no human protocol established.

—

Human evidence

None — no published clinical trials

All dosing extrapolated from animal models.

—

Detection in doping

Full-length MGF detected via LC-MS in illicit productsThevis 2014

WADA-prohibited since 2005; no therapeutic indication.

—

Evidence basis

Animal models + in vitro only

Animal mechanistic / in vitro onlyFedoreyeva 2011

Typical protocol (anecdotal)

—

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

Frequency

—

Once daily or alternate days

Cycle length

—

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

Route

—

Subcutaneous

Reconstitution

—

Sterile water or bacteriostatic saline

Half-life

—

Unknown — likely minutes (short peptide)

04Side Effects & Safety

Parameter

MGF

Testagen

Human safety data

None — no clinical trials published

—

Theoretical IGF-1 axis risk

Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)

—

Tumor promotion

IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer

—

Antibody development

Unknown — no longitudinal human exposure data

—

Local injection reaction

Presumed similar to other peptides (erythema, induration) — no direct evidence

—

Dysregulated expression with age

Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018

—

Injection site reactions

—

Erythema, mild irritation (potential)

Systemic effects

—

Unknown — no human safety data

Hormonal impact

—

No published data on testosterone, LH, FSH effects

Long-term safety

—

Unknown — no long-term studies

Absolute Contraindications

MGF

·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
·No established therapeutic use — investigational only

Testagen

·Active testicular malignancy

Relative Contraindications

MGF

·Family history of IGF-1-axis malignancies
·Use outside research setting

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

05Administration Protocol

Parameter

MGF

Testagen

1. No validated protocol

MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

2. Synthetic peptide form

Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

3. Animal delivery models

Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015 Shioura 2014

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

4. WADA prohibition

MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

5. Research context only

Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

06Stack Synergy

MGF

+ BPC-157

Multi-pathway

View BPC-157 →

MGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.

MGF: No established dose
BPC-157: 250–500 mcg SQ near injury site
Context: Animal models only
Primary benefit: Theoretical multi-tissue repair (muscle + tendon/ligament)

+ TB-500

Moderate

View TB-500 →

TB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.

MGF: No established dose
TB-500: 2–5 mg SQ weekly
Context: Animal models only
Primary benefit: Satellite cell activation + enhanced migration/angiogenesis

Testagen

— no documented stacks